0: The morbidity and mortality of lung cancer has been the highest among all types of cancers, so it is the most common form of malignancy worldwide [ 1].
1: Lung adenocarcinoma (LUAD) is a major pathological subtype of non-small cell lung cancer (NSCLC), which approximately accounts for 40% of lung cancer cases [ 2].
2: Surgery, chemotherapy, radiotherapy, and targeted therapy are the conventional methods of treating patients with NSCLC; however, the prognosis of these patients has been unsatisfactory till date [ 3].
3: Since the past decade, immune checkpoint inhibitors (ICIS) have been used to treat patients with NSCLC, and they have modified the treatment pattern of this refractory disease [ 4].
4: Tumor-infiltrating immune cells (TIICs) have impacted the immune system and tackled abnormal biological behaviors in a complex way, so they play a key role in eliciting the bodys response to immunotherapy [ 5].
